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Background: Glioblastoma multiforme (GBM) is the most aggtessive primary brain tumor in
adultswith dismal prognosis due to the unavailability of an effective therapy. Up to now, there had
been no definitive studies published on EGFR inhibition therapy as a chemosensitizer for GBM
therapy using Temozolomide (TMZ). This study aims to reveal the most effective method and timing
to administerTMZ-anti EGFR targeted therapy which causes maximal DNA damage on GBM cells.
Methods: Various regimens of anti EGFR monoclonal antibody Nimotuzumab (NMZ) was
administered in different cornbinations with TMZ, performed on U87MG MGMT(+) EGFR(+) cells'
The effectiveness of the combinations were evaluated by measuring yH2AX levels which reflects the
degree of DNA damage. One-way Anova and LSD tests were performed to determine the effects of
"uih 
t..ut1n"nt with p<0.05. Results and discussion: the mean SD of yH2AX of each treatment was:
ll,g0+1,25 for the control group; 29.33+1.91forNMZ alone; 28.13*1.58 for TMZ alone;41.53+3.51
forconcurrentuse:35.67+2.65 forNMZ after24 hoursTMZ;31.87+2.94 forNMZafter48hours
TMZ: 39.57+4.2 for TMZ after 24 hours NMZ; and 35.93 +3.56 for TMZ after 48 hours NMZ. The
administration of TMZ concurrent with or after 24 hours NMZ gives the highest amount of DNA
damage to GBM cells. Conclusion: The administration of Nimotuzumab targeted therapy up to 24
hourJefore Temozolomide chemotherapy has been proven to be effective in maximizing the amount
of DNA damage done to GBM cells in vitro.
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INTRODUCTION
Glioblastoma multiforme (GBM) is the most
frequently found and most aggressive glial cell
tumor, associated with a dismal prognosis and
mean survival time of one year after diagnosis.r'2
This poor prognosis is caused by our incomplete
understanding on this aggressive tumor's
characteristics and the lack of an effective therapy.
The standard chemotherapy agent for GBM is
Temozolomide (TMZ).3 Many studies have been
performed to overcome TMZ resistance, including
modifications to administration dosage and
mechanism, and the combination of TMZ with
other agents or targeted therapies. Currently
available targeted therapy for GBM include PI3-
IVmTOR, PDGFR, VEGF/angiogenesis, Hedgehog
GLII and EGFR/ EGFRvIII.a-7
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Overexpression and amplification of
epidermal growth factor receptors (EGFR) is a
dominant mutation of GBM cells, compared to
other genetic mutations, and is linked to increased
GBM cell resistance to radiotherapy and
chemotherapy.t Chen, et al in 2007 have identified
the radioprotective function of EGFR, through
intranuclear translocation and its interaction with
DNA-dependent protein kinase (DNA-PK), a key
component of non-homologous end-joining
pathway in DNA repair." Even though Bao et al did
not evaluate the pathways of DNA repair caused by
induction of cytotoxic chemotherapy,'" an
analogous mechanism may be at work here. By
attempting to intemrpt the DNA repair mechanisms
of EGFR at an early stage, anti EGFR Monoclonal
Antibody Nimotuzumab (NMZ) was given before
TMZ therapy, in hope of achieving a synergistic
effect as a model of TMZ therapy for GBM cells'
This study hopes to discover the effect of
combination TMZ-NMZ therapy to find out the
most effective chemotherapy regiment for MGMT
methylated (+) and EGFR overexpression (+) GBM
wwlar.ois.unud.ac.id
cells, especially in its DNA damage activity.
Another goal for this study is to find the most
effective administration order and interval.
MATERIALSAND METHODS
U87MG cell line culturing
Expansion and maintenance of U87MG cells
were done on the bottom surface of 150 cm2 TC
flasks, submerged with 30 ml of growth medium.
The growth medium consisted of Dulbeco's
Modified Eagle's Medium (DMEM) [Gibco], l0%
Fetal Bovine Albumin (FBS) [Invitrogen], 0.5% L-
Glutamine [Gibco], and, 0,5o/o Gentamycin [Gibco].
After confluence some cells were transfened into
new flasks for further expansion or experiment
treatments. Some were added l0% Dimethyl
Sulfoxide (DMSO) [Sigma] into its medium and
frozen in cryovials submerged in liquid nitrogen as
future usage stocks. Upon usage, DMSO were
cleared off the cells by pelleting and replacing the
medium as soon as it thawed.
Drug dosage determination
Cells were planted 3 days prior to
Nimotuzumab (NMZ) and Temozolomide (TMZ)
treatments, on 24-wells plate, submerged in growth
medium. Each well was given 0, 10, 50, 100, 500,
1000 ug/ml NMZ, and 0,2,10,20, 100, 200 pg/ml
TMZ. Each treatment was done in duplet. Cells
were obseryed under microscope every 24 hours for
number and viability.
After 24 hours, the other duplet had its
medium aspirated dry, harvested by submerging
with 0.1% trypsin [Gibco] for 5 minutes at 37C.
Cells from each well then were suspended in 500 pl
PBS and analyzed by flow cytometry as separate
samples: the whole 500 pl PBS of each sample was
run through flow cytometer and had its approximate
total cell number recorded by the program. Optimal
drug concentration was also determined by these
cell numbers.
U87MG drug treatment
Cells were planted 3 days prior to
Nimotuzumab (NMZ) and Temozolomide (TMZ)
treatments, on 3xl2-wells plates, submerged in
growth medium. Then on the third day, cells were
treated with 8 different treatments. 4 wells were
allocated for each of these treatment groups: Non-
treated (Control), NMZ only for 72h (N), TMZ
only for 72h (T), NMZ and TMZ for 72h (NT),
NMZ after T4tTMZ (N24T), NMZ after 48hTMZ
(N48T), TMZ after 24h NMZ (T24N), and TMZ
after 48h NMZ (T48N). NMZ was given at 1000
pglml and TMZ at 20 pg/ml in their respective
treatment groups, both based optimal drug
concentration determined beforehand. The rest 4
wells were reserved as spare wells in case anything
unexpected happened to any of the allocated wells
prior to cell treatment, to ensure the cells within all
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wells to be treated were in possible best conditions
and closest to identical numbers. Unused spare
wells were later on used as flow-cvtometrv
unlabeled control.
U87MG flow cytometry
After 72 hours of treatments, cells were
harvested by submerging with 0.1% trypsin [Gibco]
for 5 minutes at37C. Every treatment group had 4
wells available to stain with fluorescent tagged
antibody. Each of these 4 wells was allocated to be
stained with anti-yH2AX-APC [Cell Signaling] to
analyze cell DNA damage of the samples.
After trypsination, each well content was put
into a single 1.7 ml microtube and washed once
with staining buffer (PBS [Invitrogen] + l% BSA
[Sigma]) to remove the trypsin. Each tube which
was allocated for anti-CDl33-APC staining were
directly resuspended with 50 ul staining buffer and
added with I ul anti-CDl33-APC and incubated for
I hour in a dark room at room temperature.
All other samples were next fixated by
resuspending them with l%o formaldehyde inside
each micro-tube and incubate them all for l0
minutes at 370C, and then were washed with
staining buffer to remove the formaldehyde. For the
wells allocated for anti-yH2AX-APC,
permeabilization of the outer plasma membrane and
nuclear envelope was done by resuspending the cell
pellet with l% Triton-X [Biorad] in staining buffer
and incubate them for 30 minutes at room
temperature. Soon after permeabilization step, each
of the samples were washed twice with staining
buffer and then resuspended in 50 pl staining buffer
in their own respective microtubes. After that, each
microtube was added with anti-yH2AX-APC. All
tubes were incubated for I hour in a dark room at
room temperature.
After all treatment groups had been incubated
for an hour. each tube was added with 450 ul of
staining buffer, making each sample 500 ul in
volume. Finally all samples were analyzed with
flow cytometer [BD Accuri C6]. Samples with
FITC fluorescent marker were excited by 488 nm
blue laser and read at 533-563 nm wavelength
channel, PE by 488 nm blue laser at 585-625 nm
wavelength channel, and APC by 640 nm red laser
at 675-700 nm wavelength channel.
Statistical analysis
Statistical analysis was performed using the
SPSS for Windows, version 21.0. The significance
of differences between groups was compared using
One Way Anova. The significance of differences in
groups was compared using LSD. Differences were
considered significant ifp < 0.05.
RESULTS
The results of flowcytometer examination of
each treatment was presented in table and graph
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form. Of each treatment group have
CDl33negative. yH2AX levels are significantly
higher (p < 0.05) for all treatment protocols
compared to the control group.
Table I The Effects of NMZ, TMZ and Their
Combinations to vH2AX Levels.
yH2AX levels (%)
Groups N Difference inMean from
Control
the combined NMZ and TMZ groups vary
depending on their administration order and
administration interval. The highest yH2AX levels
are found in the concurrent therapy group (mean
41.53+3.51), and lowest in the NMZ after 48 hours
TMZ group (mean 31.87+2.94).The differences are
significant between the concurrent therapy group
and the N24T, N48T and T48N groups; but not
significant between the concurrent group and the
T24N group.
DISCUSSION
Repair of DNA damage in GBM cells
This is a pioneer study in investigating the
effect of the administering NimotuzumabNMz (N)
on the effectiveness of Temozolomide/TMZ (T)'
assessing the effects of the order of administration
and the interval between administrations on the
degree of DNA damage as represented by yH2AX
levels. Higher yH2AX levels are interpreted as a
higher degree of DNA damage. The highest
significant yH2AX levels were identified when
Temozolomide and Nimotuzumab were given
concurrently, or when Temozolomide was given
after 24 hours Nimotuzumab; compared to the
yH2AX level in the control group' yH2AX levels
increase by degrees between the T, N, N48T,
N24T, T48N, T24N and NT groups. The combined
use of Temozolomide and Nimotuzumab is proven
to increase the degree of DNA damage
significantly, when compared to the control group
and monotherapy groups.
The repair of double-stranded DNA damage
(DNA double strain breaks, DNA DSBs) is achieved
through two pathways. The first pathway is to
combine a sequence of DNA with a homologous
template (homologous recombinant, F1R), and the
second pathway is to combine the end sequence of
damaged DNA based on the presence of proteins
and sequential systems (non homologous-end
joining, NHEO. NIIEJ is the dominant pathway in
repairing DNA DSBs, with the HR pathway as a
supporting pathway.e The NFIEJ pathway is active
during the cell cycle, and occurs mostly at the Gl
phase; the HR pathway happens after DNA
replication was performed, where identical
chromatins are used as a template in the repair
process.tt
In the NFIEJ pathway, recombination the
damaged DNA chains depend on the activity of sub
unit Ku70 dan Ku80, which is the main mechanism
for DNA recombination. They are tied to the DNA
end chains, which activates the catalytic subunit of
DNA protein kinase (DNA-PK) and Artemis, which
interacts with the proteins between the DNA-PK
molecules and forms a bridge between the DNA
end chains. The combination of DNA-PK and
Artemis becomes phosphorylated and activates
other enzymes, such as Ligase IV/XRCC4 and
polynucleotide kinase (PI'IK). Outside of the
Mean
(SD)
Control
Nimotuzumab
(I.tMT)
Temozolomide(rMz)
NandT
combinations
l5
11.90
(t.2s)'
29.33
(1.91)b
28.13
(1.580b
36,9r
(4.53)"
0.00
17.43p
16.23p
25.01q
Superscripted letters in the same column shows
LSD results after One Way Anova test showingp >
0.05; and its significant difference p < 0.05. The
group with combination therapy resulted in
significantly higher yH2AX levels when compared
to the mono-therapy groups. There are no
significant differences between single therapy NMT
orTMZ groups.
Data of yH2AX levels grouped by order of
and interval of drug administration were presented
in Table 2.
Table2
yH2AX levels grouped by order of and interval of
drug administralio4-
yH2AX levels (%)
Grouos Different in
' Mean (SD) mean from
NMZ after 48 31.87 (2.gqb D.97P
hours TMZ
(N48r)
TMZafter 48 35.93 (3.56)" 24.03c
hours NMZ
(r48N)
NMZ after 24
hours TMZ
(N24r)
TMZafter 24
hours NMZ
(124N)
Concurrent
TMZ andNMZ
use
35.67 (2.65)" 23.77c
3s.s6 (2.oqd
41.53 (3.s1)d
27.66'
29.63',
Superscripted letters in the same column shows
LSD results after One Way Anova test showing p >
0.05; and its significant difference p < 0'05.
Table 2 shows the results of various
combinations of NMZ and TMZ therapy, by order
and treatment interval. The mean yH2AX levels in
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aforementioned process, protein complexes Mrel l,
Rad 50, and Msl(MRN) are also able to recombine
and repair DNA fragments. Therefore, the DNA-
PK enzyme plays a key role in repairing DNA
DSBs.r2 EGFR also is one of themain keysin
inhibiting of DNA DSBs repair.'In NFIEJ pathway,
interactions of EGFRwith DNA-PKwill control the
disassembly of DNA-PK and the physicalrejoining
of DNA DSBs. EGFRbinds to the catalytic sub unit
of DNA-PK and controls regulatory subunits Ku70
of DNA-PK.t5 By block of EGFR translocation into
the nucleoplasm, the interactions of EGFR-DNA
PK will interupted.r3'ra
Optimal Combination for DNA Damage
The LSD statistical test was performed to
investigate the difference between the order of
administration and the interval between the
administration of Nimotuzumab and
Temozolomide. and it shows that concurrent
administration is significantly better than other drug
regiments, except the administration of
Nimotuzumab within 24 hours before the
administration of Temozolomide. This proves that
giving Nimotuzumab before Temozolomide can
inc.ease the degree of DNA damage caused by
Temozolomide. This effect is thought to be caused
by the effects of Nimotuzumab in inhibiting
intracellular translocation of EGFR, and inhibiting
the effect of DNA repair enzymes.^(DNA-PK) in
repairing DNA double strain breaks'''
- Similar drug administration order, with
different administration interval, was shown to have
a different effect; T24N has higher yH2AX levels
than T48N, and N24T has higher yH2AX levels
than N48T. This indicates that the timing of
administration has an effect on the increased DNA
damage mechanism. This study shows that the
administration of Temozolomide or Nimotuzumab
within 24 hours before the next drug can increase
DNA damage compared to 48 hours' This is
thought to be caused by a very fast reaction phase
by tlie defensive mechanism of GBM cells towards
radiochemotherapy; within l-4 hours of drug
administration, intranuclear EGFR translocation
and DNA-PK already begins to repair th^e DNA
damage caused by Temozolomide'' The
administration of Nimotuzumab within the first 24
hours is effective in inhibiting the DNA repair
process, while Temozolomide continues to .cause
bNA du.ug. and DNA double strain breaks'r6 The
administration of Nimotuzumab in the first 24
hours will inhibit the interaction and activity of
EGFR-DNA-PK enzyme, increasing DNA damage
in vitro. The inhibition of DNA repair through the
main NHEJ PathwaYs bY EGFR-DNA PK
interaction will increase the ability of
Temozolomide in causing damage to GBM cell
DNA.
CONCLUSION
The administration of Nimotuzumab,
concunently or within 24 hours before the
administration of Temozolomide. is an effective
combination in maximizing DNA damage to the
DNA of GBM cells in vitro. The initial inhibition
of DNA repair enzymes (DNA PK) through the
mechanism of EGFR blockage will synergize with
the effects of Temozolomide in causing DNA
damage.
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